[Market Focus] BuKwang Pharm Surges 13% Early on Mid- to Long-Term Vision and High-Dividend Expectations
BuKwang Pharm is experiencing an early surge of over 13% in its stock price on March 25, 2026, driven by the announcement of its mid- to long-term vision and high-dividend policy at the shareholders' meeting.
As of 9:50 a.m. on March 25, BuKwang Pharm was trading at 8,050 won on the Korea Exchange, up 13.22% from the previous session.
Previously, at the shareholders' meeting held the day before, BuKwang Pharm announced its mid- to long-term vision to join the top 20 domestic pharmaceutical companies in terms of sales by 2030.
The company also unveiled a high-dividend policy aimed at enhancing shareholder value. BuKwang Pharm decided to pay a total dividend of 12.3 billion won, combining the interim dividend of 50 won per share that was paid in November last year and the year-end dividend of 75 won per share approved at the shareholders' meeting.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
According to BuKwang Pharm, this dividend enables the company to meet the criteria for high-dividend companies, allowing shareholders to benefit from separate taxation on dividend income.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.